Primary and secondary outcomes for all patients and for the VUD subgroup
| . | Control . | Intervention . | P . | |||
|---|---|---|---|---|---|---|
| All (n = 73) . | VUD (n = 45) . | All (n = 72) . | VUD (n = 50) . | All . | VUD . | |
| GVHD (2-4) at 100 d | ||||||
| n (%) | 25 (36) | 19 (45) | 18 (27) | 14 (32) | ||
| HR (95% CI) | — | — | 0.69 (0.38-1.26) | 0.61 (0.31-1.22) | .231 | .161 |
| GVHD (2-4) at 180 d | ||||||
| n (%) | 27 (40) | 20 (48) | 19 (29) | 14 (32) | ||
| HR (95% CI) | — | — | 0.68 (0.38-1.22) | 0.59 (0.30-1.16) | .192 | .125 |
| GVHD (3-4) at 100 d | ||||||
| n (%) | 9 (13) | 4 (10) | 9 (14) | 6 (14) | ||
| HR (95% CI) | — | — | 1.04 (0.42-2.61) | 1.42 (0.41-4.95) | .930 | .585 |
| GVHD (3-4) at 180 d | ||||||
| n (%) | 9 (14) | 4 (10) | 9 (14) | 6 (14) | ||
| HR (95% CI) | — | — | 1.04 (0.42-2.61) | 1.42 (0.41-4.95) | .930 | .585 |
| TRM | ||||||
| n (%) | 6 (8) | 5 (11) | 8 (11) | 5 (10) | ||
| HR (95% CI) | — | — | 1.37 (0.48-3.96) | 0.94 (0.27-3.23) | .558 | .919 |
| Disease-related mortality | ||||||
| n (%) | 8 (11) | 5 (11) | 11 (15) | 8 (16) | ||
| HR (95% CI) | — | — | 1.42 (0.57-3.53) | 1.48 (0.49-4.51) | .454 | .488 |
| PFS | ||||||
| n (%) | 55 (75) | 34 (76) | 48 (67) | 33 (66) | ||
| HR (95% CI) | — | — | 0.69 (0.38-1.28) | 0.64 (0.30-1.33) | .240 | .235 |
| . | Control . | Intervention . | P . | |||
|---|---|---|---|---|---|---|
| All (n = 73) . | VUD (n = 45) . | All (n = 72) . | VUD (n = 50) . | All . | VUD . | |
| GVHD (2-4) at 100 d | ||||||
| n (%) | 25 (36) | 19 (45) | 18 (27) | 14 (32) | ||
| HR (95% CI) | — | — | 0.69 (0.38-1.26) | 0.61 (0.31-1.22) | .231 | .161 |
| GVHD (2-4) at 180 d | ||||||
| n (%) | 27 (40) | 20 (48) | 19 (29) | 14 (32) | ||
| HR (95% CI) | — | — | 0.68 (0.38-1.22) | 0.59 (0.30-1.16) | .192 | .125 |
| GVHD (3-4) at 100 d | ||||||
| n (%) | 9 (13) | 4 (10) | 9 (14) | 6 (14) | ||
| HR (95% CI) | — | — | 1.04 (0.42-2.61) | 1.42 (0.41-4.95) | .930 | .585 |
| GVHD (3-4) at 180 d | ||||||
| n (%) | 9 (14) | 4 (10) | 9 (14) | 6 (14) | ||
| HR (95% CI) | — | — | 1.04 (0.42-2.61) | 1.42 (0.41-4.95) | .930 | .585 |
| TRM | ||||||
| n (%) | 6 (8) | 5 (11) | 8 (11) | 5 (10) | ||
| HR (95% CI) | — | — | 1.37 (0.48-3.96) | 0.94 (0.27-3.23) | .558 | .919 |
| Disease-related mortality | ||||||
| n (%) | 8 (11) | 5 (11) | 11 (15) | 8 (16) | ||
| HR (95% CI) | — | — | 1.42 (0.57-3.53) | 1.48 (0.49-4.51) | .454 | .488 |
| PFS | ||||||
| n (%) | 55 (75) | 34 (76) | 48 (67) | 33 (66) | ||
| HR (95% CI) | — | — | 0.69 (0.38-1.28) | 0.64 (0.30-1.33) | .240 | .235 |